Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition

Improved prognosis for triple-negative breast cancer (TNBC) has currently plateaued and the development of novel therapeutic strategies is required. Therefore, we aimed to explore the anti-tumor effect of eribulin and paclitaxel combination therapy for TNBC. The effect of eribulin and paclitaxel in...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2018-05, Vol.9 (33), p.22986-23002
Hauptverfasser:	Oba, Takaaki, Ito, Ken-Ichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Research Paper
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!